Profound Nanoscale Structural and Biomechanical Changes in DNA Helix upon Treatment with Anthracycline Drugs.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Jun 2020
Historique:
received: 25 04 2020
revised: 16 05 2020
accepted: 04 06 2020
entrez: 14 6 2020
pubmed: 14 6 2020
medline: 26 3 2021
Statut: epublish

Résumé

In our study, we describe the outcomes of the intercalation of different anthracycline antibiotics in double-stranded DNA at the nanoscale and single molecule level. Atomic force microscopy analysis revealed that intercalation results in significant elongation and thinning of dsDNA molecules. Additionally, using optical tweezers, we have shown that intercalation decreases the stiffness of DNA molecules, that results in greater susceptibility of dsDNA to break. Using DNA molecules with different GC/AT ratios, we checked whether anthracycline antibiotics show preference for GC-rich or AT-rich DNA fragments. We found that elongation, decrease in height and decrease in stiffness of dsDNA molecules was highest in GC-rich dsDNA, suggesting the preference of anthracycline antibiotics for GC pairs and GC-rich regions of DNA. This is important because such regions of genomes are enriched in DNA regulatory elements. By using three different anthracycline antibiotics, namely doxorubicin (DOX), epirubicin (EPI) and daunorubicin (DAU), we could compare their detrimental effects on DNA. Despite their analogical structure, anthracyclines differ in their effects on DNA molecules and GC-rich region preference. DOX had the strongest overall effect on the DNA topology, causing the largest elongation and decrease in height. On the other hand, EPI has the lowest preference for GC-rich dsDNA. Moreover, we demonstrated that the nanoscale perturbations in dsDNA topology are reflected by changes in the microscale properties of the cell, as even short exposition to doxorubicin resulted in an increase in nuclei stiffness, which can be due to aberration of the chromatin organization, upon intercalation of doxorubicin molecules.

Identifiants

pubmed: 32531996
pii: ijms21114142
doi: 10.3390/ijms21114142
pmc: PMC7312087
pii:
doi:

Substances chimiques

Anthracyclines 0
Antibiotics, Antineoplastic 0
DNA, Single-Stranded 0
Intercalating Agents 0
Epirubicin 3Z8479ZZ5X
Doxorubicin 80168379AG
Daunorubicin ZS7284E0ZP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Phys Chem B. 2014 Feb 6;118(5):1288-95
pubmed: 24417409
Semin Cell Dev Biol. 2020 Feb;98:181-191
pubmed: 31112797
Cardiovasc Toxicol. 2007;7(2):56-60
pubmed: 17652804
J Struct Biol. 2003 May;142(2):241-6
pubmed: 12713951
Nat Struct Biol. 2001 Jul;8(7):606-10
pubmed: 11427891
Cancer Res. 2001 Mar 15;61(6):2467-71
pubmed: 11289116
Chem Rev. 2014 Mar 26;114(6):3087-119
pubmed: 24443844
Eur Biophys J. 2016 May;45(4):287-99
pubmed: 26646261
Cell. 1995 Aug 11;82(3):405-14
pubmed: 7634330
PLoS One. 2019 Nov 20;14(11):e0224936
pubmed: 31747397
Biophys J. 1997 Mar;72(3):1335-46
pubmed: 9138579
Science. 1996 Feb 9;271(5250):795-9
pubmed: 8628994
Biochemistry. 1999 Dec 7;38(49):16067-75
pubmed: 10587429
Bioessays. 2005 Jan;27(1):50-6
pubmed: 15612030
Int J Nanomedicine. 2015 Jan 29;10:949-61
pubmed: 25673990
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
EMBO J. 1996 May 15;15(10):2417-24
pubmed: 8665849
Drug Discov Today. 2004 Jan 15;9(2):64-71
pubmed: 15012930
Nanoscale. 2019 Mar 14;11(11):4707-4711
pubmed: 30834915
Biophys J. 2016 May 24;110(10):2151-61
pubmed: 27224480
Biochemistry. 1995 Aug 8;34(31):9962-76
pubmed: 7632695
Biochem Biophys Res Commun. 2011 Jan 7;404(1):297-301
pubmed: 21130075
Integr Biol (Camb). 2012 May;4(5):568-74
pubmed: 22513758
Prog Biophys Mol Biol. 2000;74(1-2):115-40
pubmed: 11106809
Angew Chem Int Ed Engl. 2014 Dec 15;53(51):14135-8
pubmed: 25331678
Mutat Res. 2007 Oct 1;623(1-2):3-13
pubmed: 17445837
Biomed Pharmacother. 2018 Jan;97:1195-1203
pubmed: 29136959
Curr Drug Metab. 2015;16(6):412-26
pubmed: 26321196

Auteurs

Aleksandra Kaczorowska (A)

Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Weronika Lamperska (W)

Department of Optics and Photonics, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Kaja Frączkowska (K)

Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Jan Masajada (J)

Department of Optics and Photonics, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Sławomir Drobczyński (S)

Department of Optics and Photonics, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Marta Sobas (M)

Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4, 50-367 Wroclaw, Poland.

Tomasz Wróbel (T)

Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4, 50-367 Wroclaw, Poland.

Kinga Chybicka (K)

Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wroclaw, Poland.

Radosław Tarkowski (R)

Department of Surgical Oncology, Provincial Specialist Hospital, Iwaszkiewicza 5, 59-220 Legnica, Poland.

Sebastian Kraszewski (S)

Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Halina Podbielska (H)

Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Wojciech Kałas (W)

Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wroclaw, Poland.

Marta Kopaczyńska (M)

Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, 27 Wybrzeze Wyspianskiego, 50-370 Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH